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Introduction. 
In recent years there has been a concerted effort to establish the phenotype of prodromal /pre-
dementia  Alzheimer’s disease (AD). 1,2 The terminologies used for this state have varied, the current 
position being that a diagnosis of AD now encompasses both the pre-dementia and dementia 
phases, and is diagnosed on the basis of the presence of an early and significant episodic memory 
impairment and in-vivo biomarker evidence of Alzheimer’s pathology. 3 There have also been 
initiatives to characterize the pre-dementia phase of Parkinson’s Disease (PD), currently referred to 
as PD-MCI (mild cognitive impairment)4,5 and to a lesser extent the prodromal features of PD itself.6   
The justification for these shifts to earlier diagnosis is that preventative treatment for 
neurodegenerative disorders will be most effective if given before extensive neurochemical and 
anatomic pathological changes have occurred in the brain. This argument has gained considerable 
force from the failure of several amyloid modifying agents to demonstrate clinical benefits in 
populations with mild to moderate AD. Trials of potential preventative agents in earlier stages of 
disease will only be possible once reliable methods of prodromal diagnosis have been established.  
The purpose of this brief paper is to consider the issues surrounding development of a definition and 
methods for determining a pre-dementia/prodromal diagnosis for patients who later progress to 
dementia with Lewy bodies (DLB).  Before doing so it is helpful first to review the current situation 
regarding diagnosis of DLB at the dementia stage. 
Clinical diagnostic concepts and methods for DLB have evolved over the last three decades to 
incorporate a variety of different terminologies including diffuse LB disease (DLBD)7 8,9, LB dementia 
(LBD) 10, dementia associated with cortical Lewy bodies (DCLB) 11, the LB variant of Alzheimer’s 
disease (LBVAD) 12,13, and senile dementia of LB type (SDLT) 14.  Dementia with Lewy bodies (DLB) 
was eventually agreed as a term to include all of these within operationalised consensus criteria 15,16.  
The latest restatement of these criteria are manifest by their inclusion as neurocognitive disorder 
with Lewy bodies (NCDLB) in the latest revision of DSM-5 17. This formal recognition of DLB as a 
diagnostic category equivalent in rank to others such as AD, vascular cognitive impairment and 
fronto-temporal  dementia will inform and empower patients and families in legal and clincal issues 
such as advance care planning, treatment of non-cognitive symptoms and sensitivity to antipsychotic 
prescription . It will also enable clinical and research practice, and has major implications for 
reimbursement and regulatory authorities.  It reflects a general recognition of the importance of 
non-Alzheimer dementias as common disorders that require a different approach both in the clinic 
and the laboratory.  
 
Consensus Criteria for DLB. 
The consensus clinical diagnostic criteria for DLB have been in widespread use for almost two 
decades. Such criteria identify probable and possible DLB cases, depending upon the number of core 
and suggestive features present, both levels requiring the presence of dementia defined as “ a 
progressive cognitive decline of sufficient magnitude to interfere with normal social or occupational 
function”.  By definition, therefore, the consensus criteria exclude individuals  at a pre-dementia 
stage. As originally conceived they were shown to have a high specificity for clinical DLB diagnosis 
compared with autopsy validation 18, but apparently failed to detect a significant number of 
eventually proven Lewy body (LB) pathology cases, their  sensitivity ranging from 0-83%  with a 
mean of around 40%19. In order to address this perceived insensitivity the DLB Consortium met again  
to resolve improving the identification of cases ante-mortem.     No major amendments to the 
previously described core features of DLB were proposed, namely  fluctuating cognition with 
pronounced variations in attention and alertness;  recurrent visual hallucinations that are typically 
well formed and detailed; and spontaneous motor features of parkinsonism, but improved methods 
for their clinical assessment were recommended.   A new category of features “suggestive” of DLB 
was added comprising REM sleep behaviour disorder (RBD), severe neuroleptic sensitivity, and 
abnormal dopamine transporter neuro-imaging imaging.   It was proposed that if one or more of 
these suggestive features was present, in addition to one or more core features, a diagnosis of 
probable DLB could be made.   Possible DLB was to be diagnosed if one or more suggestive features  
were present in a patient with dementia even in the absence of any core features.  16.  
The Lewy body variant of Alzheimer’s disease, or AD with Lewy bodies? 
The improved consensus criteria have been suggested to detect 25% more DLB cases than the 
previous version 20 although a retrospective application of the new criteria to an autopsy verified 
sample reported that cases with Braak stage 5 and 6 Alzheimer tangle pathology are still unlikely to 
be correctly clinically diagnosed. Such cases tend to lack core or suggestive DLB features, and 
clinically resemble AD21.  It has also been shown that the DLB clinical syndrome is modified by the 
severity of Alzheimer neuritic plaque pathology, although total β-amyloid load has no effect. 22  This 
is consistent with the original proposition that the likelihood of a patient having the typical DLB 
clinical syndrome is “directly related to the severity of Lewy-related pathology and inversely related 
to the severity of concurrent AD-type pathology.” 16  Given that AD-type pathology is frequently 
present in DLB, there will therefore always be a significant number of patients who will prove very 
difficult to identify solely on clinical grounds .  This group are best described pathologically as AD 
with LB or as LBVAD.12  It is difficult to estimate the proportion that fall into this category but it is 
probably reasonable to assume that they account for most of the difference in the prevalence of all 
dementia cases reported to have cortical LB pathology at autopsy (10-15%)23, and the clinically 
diagnosed  prevalence in secondary care services from which such autopsy series are usually derived 
(7.5%)24.  In other words, only a half of  DLB pathology cases look clinically like typical DLB and they 
are probably accurately diagnosed once the patient reaches a suitably qualified diagnostician. An 
equal number of cases will however have a different clinical presentation which may be difficult or 
impossible to distinguish  from AD; intermediate between AD and DLB, or atypical in some other 
way. 
From a clinicians’ perspective it might be easier to conclude that these cases are not DLB and that an 
additional diagnostic category such as  LBVAD or AD with LBshould be reintroduced.  DLB would then 
become a very clearly circumscribed clinico-pathological syndrome, i.e. with both high diagnostic 
specificity and sensitivity.  Identification of the LBVAD/ADLB  group would remain problematic, since 
the anticipated characteristics of the clinical presentation remain uncertain.  It would seldom 
correspond to the recently proposed IWG2 group “mixed-AD” category, since such patients require 
two of the three DLB core clinical features i.e. also fulfil DLB criteria.  More likely they would present 
as atypical AD or even typical AD,with an additional requirement for the presence of at least one LB 
biomarker. Engagement with the Alzheimer diagnostic community over these important overlap 
cases should be a priority.   
Prodromal LB disease 
The constellation of clinical features that have been suggested as indicative of early LB disease are 
listed in table 1.  These symptom lists have been derived by asking patients at their time of diagnosis 
with PD and DLB, about their experience of these symptoms in the ten to fifteen year period prior to 
presentation. 6,25,26  These earlier symptoms of sleep disturbance and autonomic involvement have 
long been recognized by researchers as part of the Lewy body spectrum but they are often not 
enquired about in clinical practice and their non-specific nature may make them not useful as early 
markers, e.g. constipation and dizziness are very common in the older population whether Lewy 
body disease is present or not.  Although subject to recall and retrospective biases, such reports are 
remarkably consistent both in the items mentioned and their relative timings making it evident that 
the prodromal symptoms of PD and DLB overlap substantially. This suggests that at the very earliest 
stage of LB disease it may not be possible to predict which phenotypic pathway they will 
subsequently follow and the only realistic diagnostic label at this early stage  is of “symptoms 
suggestive of prodromal LB disease”. Since most such symptoms can be caused by multiple other 
causes in older people, their positive predictive value for LB disease is likely to be minimal and  a LB 
biomarker needs be incorporated in order to increase disease specificity for a prodromal LB disease 
entity.  The clinical utility of such a broad diagnostic category as prodromal LB disease is however 
questionable and requires further consideration which is outside of the scope of this paper. The 
prognostic implications of a clinical diagnosis of rapid eye movement sleep behaviour disorder (RBD) 
a diagnosis of which has already been shown to be predictive not just of DLB but also PD and multi-
system atrophy (MSA) and highly associated with later progression to autopsy confirmed LB 
disease27,28  particularly requires further elaboration.  
 
Prodromal /pre-dementia DLB.   Progression and validation. 
Figure 1 offers a simple starting point for a consideration of the introduction of a pre-dementia stage 
into the DLB diagnostic process and which assumes progression to an eventual dementia state. 
FIGURE 1 HERE 
The term “typical DLB” has been used in figure 1 to capture all those cases which are  recognizable 
by the clinician by virtue of meeting Consensus criteria for probable or possible DLB.  In many such 
cases a confident diagnosis of DLB will be made on clinical grounds alone and biomarker 
confirmation may not be required. In other cases when the clinician is less confident, additional 
biomarker evidence will  be required. It is apparent from figure 1 that a patient presenting with 
prodromal DLB may progress either to typical DLB, or to atypical DLB and the above data suggest 
that these may be approximately equally likely events .  This poses some difficulties for the 
validation of a prodromal DLB diagnosis, since progression to a more typical state over time is the 
usual standard.  Given that this is the case it is apparent that there will be a need for biomarker 
confirmation of LB pathology not only at the prodromal stage, but also at the dementia stage for 
atypical cases.  The situation is simplified if DLB-dementia is restricted to typical cases only, i.e. if 
atypical cases are regarded as  LBVAD/ADLB as argued earlier. It is not clear what to call these 
prodromal cases who eventually progress to atypical DLB, but the reality for many prodromal 
dementia cases may be that a mixed pathology diagnosis is more appropriate and will be defined by 
a non-specific clinical presentation and multiple biomarker abnormalities.  Again this is a topic which 
needs debating with the wider dementia diagnostics community. 
Returning to the more straightforward situation of prodromal, progressing to typical DLB, an 
important question is which biomarker(s) might be most useful to detect it early. An abnormal 
striatal dopamine transporter uptake scan has been established as useful in DLB-dementia and could 
be a helpful test in the pre-dementia situation.29 But post-mortem studies have demonstated that up 
to 50% of cases with synuclein pathology do not have substantial mid brain involvement even at 
autopsy30, so it is likely that  that many DLB patients presenting with limbic and cortical related 
symptoms will not have abnormal dopaminergic function, especially at an early stage.  More 
sensitive biomarker alternatives to support the presence of LB disease could include MIBG cardiac 
scintigraphy31, or demonstration of alpha-synuclein in biopsy of sub-mandibular gland32, sigmoid 
colon33 or cutaneous nerve34.  All of these, however, need robust demonstration of sensitivity and 
specificity in typical and atypical DLB dementia cases before they can be extended to confirming 
diagnosis at a pre-dementia stage.   
 
 
 
Prodromal DLB subtypes – proposal of a broader classification 
It is apparent from the previous discussion that pre-dementia DLB may have one of several  broad 
clinical profiles, a situation which differs from AD in which a mild cognitive impairment is generally 
considered as the key prodrome. Prodromal DLB should  only be suspected when the pattern of 
early clinical symptoms is suggestive of higher CNS involvement, i.e. is already leading to cognitive or 
psychiatric features. Three such  prodromal DLB subtypes are considered below – see figure 2. Other 
early symptoms can only be interpreted as indicative of prodromal LB disease in general, or in the 
case of early motor symptoms, of prodromal PD.  
The mild cognitive impairment variant (DLB-MCI) is the most obvious of these and there is already 
good evidence suggesting that this is usually non-amnestic, multi-domain in type and possibly 
associated with early visuoperceptual and attentional deficits35.  Conversion to DLB in such patients 
may occur even more frequently than conversion to AD in patients with amnestic MCI.   DLB-MCI 
broadly corresponds to the DSM-5 category of mild neurocognitive disorder with Lewy bodies. 17  
A delirium onset DLB (DLB-del), with provoked or spontaneous delirium as the presenting features 
has also been described,36 37 often occurring months or years prior to dementia onset and present in 
up to 25% of DLB cases compared with only 7% of AD38.  There have been no systematic studies of 
the frequency of LB disease in patients presenting with delirium although phosphorylated alpha-
synuclein pathology in myenteric plexus was found in 44% of gastrectomy39 patients having a  post-
operative delirium compared with only 6% in those who did not.  The implications for management 
of delirium with antipsychotic agents are clear. Also described in the literature but not widely 
recognized  is a psychiatric disorder DLB (DLB-psych) with its primary presentation as a late-onset 
affective disorder or psychosis36, typically treatment refractory and with adverse sensitivity to 
neuroleptic and other psychotropic agents.40 Mild cognitive and neurological deficits are often 
present at an early stage but the underlying basis is unsuspected until revealed by appropriate 
neuroimaging or disease progression. 
Conclusions. 
Prodromal DLB criteria will as a minimum, require a person to meet clinical criteria for one of these 
prototypic syndromes (MCI, delirium-onset or psychiatric onset) accompanied by at least one 
biomarker supportive of Lewy body disease. The next step  is to clarify these concepts before moving 
to test them in suitable samples of patients and with suitably selected and disease staged 
biomarkers.  
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Bi
om
ar
ke
r
Typical 
DLB
Atypical 
DLB
Prodromal
DLB
Prodromal / pre-dementia DLB
DLB- mild cognitive impairment onset
DLB-mci
DLB-delirium onset
DLB-del
DLB-psychiatric onset 
DLB-psych
may present as
Early symptoms –typically 5-15 years pre-dementia 
Decreased sense of smell 
REM sleep behavior disorder 
- nightmares  
-  crying or shouting during sleep 
   - limb movements during sleep 
Constipation 
Dizziness on standing 
Urinary incontinence 
Increased saliva 
Increased sweating 
 
Intermediate symptoms  
Delirium – provoked or unexplained 
Late onset psychiatric disorder  
- psychosis 
- depression 
 
Later symptoms  
Cognitive impairment 
Visual hallucinations 
Parkinsonism 
 
Table 1 
Clinical features that have been suggested as indicative of early LB disease 
